Atle Fund Management AB Purchases New Position in IDEAYA Biosciences, Inc. $IDYA

Atle Fund Management AB purchased a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 4th quarter, HoldingsChannel reports. The fund purchased 97,438 shares of the company’s stock, valued at approximately $3,368,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Arizona State Retirement System increased its holdings in IDEAYA Biosciences by 1.5% in the 3rd quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock valued at $635,000 after purchasing an additional 353 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its holdings in IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after purchasing an additional 436 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in IDEAYA Biosciences by 16.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after buying an additional 537 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after buying an additional 580 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Jeffrey Stein purchased 50,000 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were acquired at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the completion of the acquisition, the director directly owned 54,281 shares of the company’s stock, valued at $1,789,101.76. The trade was a 1,167.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $28.32 on Wednesday. IDEAYA Biosciences, Inc. has a 12 month low of $17.83 and a 12 month high of $39.28. The firm has a market capitalization of $2.49 billion, a PE ratio of -17.70 and a beta of -0.04. The company’s 50 day simple moving average is $31.26 and its 200 day simple moving average is $32.85.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $5.04 million. The business’s quarterly revenue was down 39.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.82) EPS. Sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IDYA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Tuesday, April 21st. Royal Bank Of Canada increased their price target on shares of IDEAYA Biosciences from $49.00 to $53.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Wall Street Zen raised shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Citigroup increased their price target on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, Wedbush increased their price target on shares of IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Fifteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.69.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.